Use of Beta-agonists in Stable Severe Congestive Heart Failure

• Status: Unknown status
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rabin Medical Center
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• Ambulatory Patients with a diagnosis of ischemic and non-ischemic cardiomyopathy with a measured EF <35%, class III as defined by the NYHA with ICD and who receive optimal pharmacological therapy.

Exclusion Criteria:

• Heart Failure class I, II, IV

• atrial fibrillation

• any significant valvular disease

• chronic obstructive pulmonary disease who treated with inhaled β2 agonist

• significant kidney disease with eGFR <30%

• severe uncontrolled electrolyte abnormalities

• prior allergic reaction to Salbutamol

• Pregnancy and nursing women